OSE Immunotherapeutics SA ORPOF
4.43 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
Day range unavailable
4.43 52-week range 11.60
- YTD
- -61.81%
- 1 year
- -61.81%
News
seekingalpha.com OSE Immunotherapeutics SA (ORPOF) Discusses Tedopi in Non-Small Cell Lung Cancer After Chemo-Immunotherapy Transcript OSE Immunotherapeutics SA (ORPOF) Discusses Tedopi in Non-Small Cell Lung Cancer After Chemo-Immunotherapy Transcript
seekingalpha.com OSE Immunotherapeutics SA (ORPOF) Lusvertikimab Mechanism and Clinical Progress in Ulcerative Colitis and Chronic Pouchitis Transcript OSE Immunotherapeutics SA (ORPOF) Lusvertikimab Mechanism and Clinical Progress in Ulcerative Colitis and Chronic Pouchitis Transcript
seekingalpha.com OSE Immunotherapeutics SA (ORPOF) Discussion of Tedopi Immunotherapy Pipeline and Clinical Progress Across Oncology Indications Transcript OSE Immunotherapeutics SA (ORPOF) Discussion of Tedopi Immunotherapy Pipeline and Clinical Progress Across Oncology Indications Transcript
globenewswire.com OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
globenewswire.com OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in Europe Gross proceeds could amount to €19.3 million based on…
globenewswire.com OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026,…
globenewswire.com OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1 €22.7 and €17.0 million cash position as of December 31, 2025, and…
globenewswire.com OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S.…
globenewswire.com OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in…
globenewswire.com OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meet
globenewswire.com OSE Immunotherapeutics Evolves its Leadership Team OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA…
globenewswire.com OSE Immunotherapeutics to Present at Upcoming Investor Conferences Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in…
globenewswire.com OSE Immunotherapeutics Announces its 2026 Financial Calendar Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. Information Date* 2025 Full-Year Financial…
globenewswire.com OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no…
globenewswire.com OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers…
globenewswire.com OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:…
seekingalpha.com OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation Transcript OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation Transcript